Cadrenal Therapeutics, Inc. (CVKD) Key Metrics
CVKD valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $3.4M
- Enterprise value
- $347,553
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.2 10-yr median 2.4
- EV / EBITDA
- 0.2
- Dividend yield
- —
- Beta
- 1.95
CVKD key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCVKD valuation Price multiples at each fiscal year-end price.
CVKD returns How much profit the business earns on the capital it uses.
CVKD per-share figures Results divided by the shares outstanding at year-end.
CVKD financial health Debt, liquidity and how easily interest is covered.
CVKD valuation history
CVKD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CVKD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CVKD cash returned to shareholders
CVKD price vs earnings per share
CVKD key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $13.5M | $17.7M | $9.6M | — |
| Enterprise value | $9.5M | $7.7M | $1.3M | — |
| Price / book | 4.9 | 2.4 | 1.3 | — |
| Earnings yield | −97.9% | −60.3% | −86.7% | — |
| Free cash flow yield | −93.2% | −41.7% | −36.7% | — |
| Shareholder yield (dividends + buybacks) | 2.2% | 0.0% | — | — |
| Share price at fiscal year-end | $6.78 | $14.49 | $11.10 | — |
| Per share | ||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$6.64 | −$8.73 | −$9.63 | −$8.66 |
| Operating cash flow per share | −$6.32 | −$6.03 | −$4.07 | −$1.69 |
| Free cash flow per share | −$6.32 | −$6.04 | −$4.07 | −$1.70 |
| Cash per share | $2.01 | $8.21 | $9.68 | $0.04 |
| Book value per share | $1.37 | $6.10 | $8.86 | −$7.16 |
| Tangible book value per share | $1.37 | $6.10 | $8.86 | −$7.16 |
| Capex per share | $0.00 | $0.01 | $0.00 | $0.00 |
| Debt per share | — | — | $0.02 | $0.83 |
| Shares outstanding | 2.0M | 1.2M | 868K | 776K |
| Change in shares outstanding | +63.5% | +40.5% | +11.9% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −260.1% | −140.8% | −780.6% | — |
| Return on assets (ROA) | −183.2% | −114.3% | −179.8% | −862.8% |
| Return on tangible assets | −305.9% | −105.2% | −98.1% | −862.8% |
| Financial health | ||||
| Total debt | — | — | $21,350 | $640,706 |
| Cash & short-term investments | $4.0M | $10.0M | $8.4M | $32,586 |
| Net debt | −$4.0M | −$10.0M | −$8.4M | $608,120 |
| Debt / equity | — | — | 0.00 | — |
| Debt / assets | — | — | 0.00 | 0.82 |
| Current ratio | 2.72 | 3.77 | 10.27 | 0.55 |
| Quick ratio | 2.72 | 3.77 | 10.27 | 0.55 |
| Interest coverage | — | — | -446.3 | -25.2 |
| Working capital | $2.7M | $7.4M | $7.7M | −$606,881 |
| Invested capital | −$1.3M | −$2.6M | −$688,775 | −$4.9M |
| Tangible asset value | $2.7M | $7.4M | $7.7M | −$5.6M |
| Net current asset value | $2.7M | $7.4M | $7.7M | −$5.6M |
| Graham net-net per share | $1.22 | $6.04 | $8.76 | −$8.12 |
| Capital allocation | ||||
| Share buybacks (net) | $291,883 | $0 | — | — |
| Capex / depreciation | 0.74 | 3.48 | 1.64 | 1.96 |
| Efficiency | ||||
| Days payables outstanding | — | 162,093.7 | 52,742.1 | 116,735.7 |
| Receivables turnover | 0.00 | 0.00 | 0.00 | — |
| Payables turnover | — | 0.00 | 0.01 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $21,624 | $37,700 | $37,248 | — |
| Average payables | $1.1M | $834,894 | $286,108 | $404,897 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from CVKD's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CVKD valuation and financial ratios
Cadrenal Therapeutics earned a return on equity of −260.1% in fiscal 2025. It returned $0.3 million to shareholders: $0 in dividends and $0.3 million in share buybacks.
See the CVKD income statement, the CVKD chart for price history, or the CVKD stock overview for the latest quote and news.
CVKD key metrics FAQ
What is Cadrenal Therapeutics's return on equity?
Cadrenal Therapeutics's return on equity (ROE) was −260.1% in fiscal 2025: net income of -$13.2 million on average shareholders' equity of $5.1 million.
Does Cadrenal Therapeutics buy back its shares?
Yes. Cadrenal Therapeutics spent $0.3 million on net share repurchases in fiscal 2025 Shares outstanding changed +63.5% over the year, to 2.0M..
What is Cadrenal Therapeutics's free cash flow yield?
Cadrenal Therapeutics generated -$12.6 million of free cash flow in fiscal 2025, a free cash flow yield of −93.2% on its market value at year-end ($13.5 million).
What is Cadrenal Therapeutics's current ratio?
Cadrenal Therapeutics's current ratio was 2.72 at the end of fiscal 2025: current assets were 2.72 times current liabilities.